Business Insider

Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Subretinal injection of ATSN-201 was well tolerated in all patients in first cohort with no serious adverse events reported Enrollment is ongoing in first clinical trial utilizing AAV.SPR, the company ...
MarketWatch

Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part ...

DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...
Seeking Alpha

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...
The American Journal of Managed Care

Gene Therapy Well Tolerated in Wet AMD, Shows Promise in Visual Acuity

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...
Dunya News

Chinese researchers develop autonomous eye surgery robot

These results demonstrate the clinical feasibility of an autonomous intraocular microsurgical robot and its ability to ...